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Abstract
Anthracyclines such as doxorubicin are used extensively in the treatment of cancers. 
Anthraquinone-related angucyclines also exhibit antiproliferative properties and have been 
proposed to operate via similar mechanisms, including direct genome targeting. Here, we report 
the chemical synthesis of marmycin A and the study of its cellular activity. The aromatic core was 
constructed by means of a one-pot multistep reaction comprising a regioselective Diels–Alder 
cycloaddition, and the complex sugar backbone was introduced through a copper-catalysed 
Ullmann cross-coupling, followed by a challenging Friedel–Crafts cyclization. Remarkably, 
fluorescence microscopy revealed that marmycin A does not target the nucleus but instead 
accumulates in lysosomes, thereby promoting cell death independently of genome targeting. 
Furthermore, a synthetic dimer of marmycin A and the lysosome-targeting agent artesunate 
exhibited a synergistic activity against the invasive MDA-MB-231 cancer cell line. These findings 
shed light on the elusive pathways through which anthraquinone derivatives act in cells, pointing 
towards unanticipated biological and therapeutic applications.
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The family of angucyclines comprises a large number of natural products formally arising 
from polyketide biosynthesis1. This family has attracted considerable attention due to the 
diverse nature of its structural variants and the widespread biological activities associated 
with them. In particular, the angucyclines display antiproliferative, antibiotic and antiviral 
properties, but the underlying mechanisms are not always fully understood1. Angucyclines 
are characterized by an anthraquinone core, reminiscent of that of known anticancer drugs, 
embedded within an extended angular aromatic backbone. Typically, the aromatic core is 
decorated by C- and O-glycosides as well as unsaturated and oxidized functionalities. 
Marmycin A (1) and B (2) are novel angucyclines, recently isolated from a marine 
Streptomyces-related actinomycete, which exhibit relevant cytotoxic properties (Fig. 1a)2. 
These natural products have caught our attention partly as a result of their unique molecular 
architecture, which contains both C- and N-glycosidic bonds organized as a complex 
hexacyclic framework. Based on structural similarities with other angucyclines, pluramycins 
and anthracyclines, the marmycins have been proposed to kill cancer cells through DNA 
targeting. For instance, the angucycline-derived jadomycin B (3) promotes the cleavage of 
double-stranded DNA in vitro upon exposure to copper and light (Fig. 1a)3. The pluramycin 
derivative hedamycin (4) intercalates within double-stranded DNA in a sequence-specific 
manner and covalently reacts with guanine residues in vitro, indicating that the flat core is 
prone to π–π stacking and some degree of hydrophobic interactions (Fig. 1a)4,5. 
Doxorubicin (DXR, 5) triggers the production of deleterious reactive oxygen species 
(ROS)6, mediates the eviction of histones7,8 and interferes with topoisomerase II to 
promote genomic instability and cell death (Fig. 1a)9,10. The notion of direct genome 
targeting is, however, confounded by landomycin E (6), a potent anticancer compound 
known to induce mitochondrial dysfunction through as yet unidentified molecular 
mechanisms (Fig. 1a)11. Similarly, the exact mechanism by which the marmycins operate 
has remained elusive. As part of our continuing efforts towards the design and synthesis of 
biologically active small molecules capable of selective genome targeting12–15, we became 
interested in dissecting the mammalian cell biology of the marmycins.
Results
Chemical synthesis of the marmycins
The limited supply of naturally occurring marmycin A (1) prompted us to establish a 
synthetic route and set up a sustainable source. Significant work in this area16–19 led to the 
construction of 7′-nor-marmycin A. For instance, remarkable Lewis acid-catalysed one-pot 
assemblies of suitable anilines and glycals have enabled the construction of the core 
structure of marmycin A devoid of the C7′ methyl group17,18. The presence of alkyl 
substituents at the junction of bicyclic systems is a ubiquitous feature of natural products, as 
illustrated by taxanes20 and steroids21, and represents a significant synthetic obstacle in 
some cases. Regardless, these pioneering studies have provided relevant clues and set 
important milestones towards achieving these complex structures. Previous expertise in 
natural product chemistry22–24 led us to consider a biomimetic route, whereby the 
marmycins could arise from the stepwise assembly of the aromatic core and a sugar derived 
from 3-epi,4-epi-vancosamine2. From a retrosynthetic standpoint (Fig. 1b), we reasoned that 
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a seco-marmycin intermediate could be obtained by reacting the aromatic triflate 7 with the 
free amine 8. Such a substrate was predicted to exhibit a sufficiently high electron density at 
C9 to allow for a late-stage cyclization upon activation of the anomeric position, despite the 
presence of the electron-withdrawing quinone fragment. However, the quaternary centre 
carrying the amine of 8 was expected to impose a high level of steric hindrance that could 
preclude an effective metal-catalysed cross-coupling of the aminosugar with the 
anthraquinone 7. Additionally, the absence of a known natural analogue functionalized with 
a glycoside at C11 hinted towards a biosynthesis involving first a C–N coupling, which in 
turn would impose the formation of the C–C bond at C9 and yield the β-epimer as the sole 
reaction product. Next, we hypothesized that the aromatic building block could be built from 
known dienophile 925 and diene 1026 through a Diels–Alder cycloaddition. This 
disconnection was, however, distinct from a biomimetic step, which formally involves 
polyketide chemistry rather than pericyclic processes. Finally, we anticipated that the 
aminosugar 8 could be readily obtained from the chiral pool 11 based on previous 
work27,28.
With this strategy in mind, we first prepared the requisite diene25 and dienophile26 from 
commercially available starting materials (Fig. 2a). Dienophile 9 was synthesized in two 
steps from naphthalene-1,5-diol 12, whereas diene 10 was prepared in five steps from 1,3-
cyclohexanedione 13 using modified procedures27. The brominated dienophile 9 and 
unprotected diene 10 were then reacted in hot toluene and stirred in methanolic potassium 
carbonate to afford a mixture of reaction intermediates and the desired cyclo-adduct 14 in 
good overall yields. Interestingly, we found that stirring the crude cycloaddition mixture in 
methanol for several hours before the addition of potassium carbonate was necessary for this 
multistep process to occur in one pot, suggesting that traces of hydrobromic acid may be 
released after cycloaddition, acting as a catalyst for dehydration and aromatization in 
methanol. Furthermore, using 10 as a protected tert-butyldimethylsilyl ether increased the 
yields of cycloaddition, but precluded dehydration/aromatization, illustrating the virtue of 
protecting group-free chemistry in some cases29. The corresponding triflate 7 was 
synthesized using a standard procedure and directly engaged in the next step. Methyl-α-L-
rhamnopyranoside 11 was used as a chiral starting material, and was first reacted with 
benzaldehyde then chloromethyl methyl ether (MOMCl), thereby enabling us to undress the 
chiral sugar via a Klemer–Rodemeyer elimination30 upon exposure of the diastereomeric 
mixture of benzylidene 15 to sec-buthyllithium in THF. The primary amine was installed in 
three steps through prior conversion of the ensuing ketone into hydroxylimine 16, which was 
then methylated in the presence of methylcerium dichloride with high diastereoselectivity. 
The intermediate compound was finally subjected to hydrogenolysis to provide the target 
diastereoisomer 8.
With the advanced building blocks 7 and 8 in hand, we explored various metal-catalysed 
cross-coupling conditions including classical palladium-mediated Buchwald–Hartwig 
chemistry31. Despite several attempts by varying ligands, solvents, bases, reaction 
temperatures and the use of microwave and flow chemistry, we were unable to produce 
sufficient quantities of the desired aniline, resulting instead in the quantitative hydrolysis of 
triflate 7 to regenerate phenol 14 along with unreacted amine 8. In contrast, tert-butyl amine 
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and other less hindered primary aliphatic amines were coupled in excellent yields using 
palladium catalysts. Further investigations led to the identification of copper as an effective 
metal for this reaction32. We found that a catalytic amount of copper iodide in hot toluene 
led to the production of the protected seco-marmycin 17 in acceptable yields, providing 
sufficient material to carry on with the next step. Notably, copper-catalysed Ullmann 
aminations are usually conducted in the presence of aromatic halides rather than triflates. 
Nevertheless, these conditions were suitable to couple the electron-deficient substrate 7 with 
the sterically demanding amine 8, where palladium chemistry had proven ineffective.
Marmycin intermediate 17 was then exposed to a series of Brønsted and Lewis acids 
including p-toluenesulfonic acid (PTSA), camphorsulfonic acid, pyridinium p-
toluenesulfonate, indium bromide, indium triflate and scandium triflate, varying organic 
solvents and reaction temperatures. These conditions led either to unreacted starting 
material, products of hydrolysis at C1′ and C4′, or the almost quantitative production of the 
free aromatic amine resulting from C3′–N bond cleavage, together with other 
uncharacterized by-products. Thus, we postulated that varying the nature of the protecting 
group of the alcohol at C4′ might provide control over conformational states in favour of a 
kinetically driven cyclization. To this end, the protected intermediate 17 was first treated 
with boron trifluoride diethyl etherate to selectively release the free alcohol 18 (Fig. 2b). To 
our surprise, all attempts to introduce another protecting group onto alcohol 18 under basic 
conditions resulted in formation of the O-cyclized product 19 (Fig. 2b), highlighting the 
dominant electrophilic nature of C9. This observation encouraged us to take advantage of 
this reactivity through the generation of the nucleophile at the anomeric position. Strikingly, 
analysis of the reaction mixture of 17 exposed to a salt of triphenylphosphonium hydrogen 
tetrafluoroborate (HPPh3·BF4) by mass spectrometry revealed the presence of a product 
displaying the molecular weight of 1. Hence, when 17 was subjected to aq. HBF4, we 
observed the formation of (+)-1 in moderate yields (Fig. 2c). This outcome was in agreement 
with a mechanism in which stringent acidic conditions activate the anomeric position, 
concurrently decreasing the electron density at C9 as a result of the protonation/chelation of 
the aromatic amine and/or the anthraquinone moiety. Conversely, milder acidic conditions 
(such as aq. HBF4) target a window of reactivity in favour of the desired intramolecular 
Friedel–Crafts reaction. Moreover, the use of water instead of dry organic solvents probably 
influenced the distribution of conformational states and thus the fate of this reaction. These 
results emphasize the dual electrophilic/nucleophilic nature of C9 and suggest that structures 
such as 19 may also be natural metabolites. As we were unable to produce marmycin B (2) 
from the synthetic sample of 1 using a nucleophilic reagent (for example, aq. HCl), we 
found that 2 could instead be obtained from 1 in the presence of N-chlorosuccinimide 
(NCS). This supports the notion that the aromatic amine increases the electron density at 
both C9 and C11, hence conferring the desired reactivity giving access to both natural small 
molecules. Although moderate reaction yields could be broadly considered intractable, we 
were able to produce appropriate quantities of rare natural products to explore the associated 
cell biology and did not seek to improve the reaction conditions further.
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Cellular activity of marmycin A
Previous work has shown that 1 exhibits cytotoxic properties against several cancer cell lines 
associated with a G1/S cell cycle arrest in ovarian A2780 cancer cells, consistent with the 
idea that 1 operates via a well-defined mechanism2. In our hands, 1 induced cell death, but 
no cell cycle arrest was detected by fluorescence-activated cell sorting (Supplementary Figs 
1 and 2). Side-by-side comparison of 1 and the clinically approved DNA intercalating agent 
DXR revealed that higher doses of 1 were required to kill human osteosarcoma U2OS cells, 
with a half-maximum inhibitory concentration (IC50) value of ~10 μM (against ~0.1 μM for 
DXR) at 72 h treatment (Fig. 3a). This result, and the fact that 1 has a rather curved 
molecular structure (Fig. 2c), suggested that 1 may operate independently of DNA 
intercalation. Interestingly, visual inspection of growing cells indicated a diffuse staining of 
the red natural product inside the cell. This prompted us to exploit this property to identify 
the subcellular localization of 1 without the need to chemically label the natural product in 
cells, as previously done by us to detect otherwise invisible small molecules14,33. Analysis 
of 1 showed an excitation at ~525 nm and fluorescence emission at ~650 nm 
(Supplementary Fig. 3). Comparative analysis of cellular staining of the minor groove DNA 
binder 4,6-diamidino-2-phenylindole (DAPI), the DNA intercalating agent DXR and natural 
product 1 using fluorescence microscopy revealed that DAPI and DXR gave a similar 
nuclear staining, while 1 did not penetrate into the nucleus but accumulated instead as small 
vesicles in the cytosol (Fig. 3b). These data strongly challenge the notion of genome 
targeting by angucycline 1. To confirm this, we studied markers of the DNA damage 
response. Little increase of phosphorylated histone variant H2AX (γH2AX), a surrogate 
mark of DNA double-strand breaks, was observed upon treatment with 1, as monitored by 
western blotting (Fig. 3c). In line with this, no phosphorylation of p53 or significant 
induction of p21 could be detected, consistent with the idea that 1 does not directly promote 
DNA damage or a checkpoint-dependent cell cycle arrest. It is noteworthy that the low 
amount of γH2AX induced by 1 was prevented by co-treatment with the caspase 3 inhibitor 
Z-DEVD-FMK, indicating some level of caspase activation and nuclease-mediated DNA 
cleavage34, characteristic of an apoptotic response. In comparison, the DNA intercalating 
drug DXR increased the level of γH2AX and induced phosphorylation of tumour suppressor 
p53 and the production of p21.
The fact that 1 is inherently fluorescent allowed us to perform live cell imaging experiments 
without the use of reagents that would otherwise alter the plasma membrane of cells. By 
doing so, we could visualize the accumulation of 1 throughout the apolar membrane, 
reflecting the lipophilic nature of the small molecule (Fig. 4a). Furthermore, this staining 
was more pronounced at some hotspots defining small vesicles of 1 sporadically 
disseminated throughout the plasma membrane, which suggested that 1 was, at least in part, 
internalized along with other components of the membrane by means of endocytosis (Fig. 
4a). We therefore attempted to identify the nature of the organelles in which 1 accumulated, 
with particular focus on endocytic compartments, in search of putative cell death 
mechanisms. Simultaneous treatment of living cells with 1 (red staining) and the lysosomal 
marker DND-22 (blue staining) led to a significant co-localization of both substrates 
(merged pink staining), characteristic of a physical proximity of these compounds in the 
lysosomes (Fig. 4a). Conversely, pretreatment with 1 prevented the accumulation of DNA-22 
Cañeque et al. Page 5













in the vesicles, further indicating that marmycin A targets the lysosomal compartment. To 
confirm this we evaluated the localization of 1 with a biological marker of this organelle. 
Cells were virally infected using the BacMam system to transiently express a green 
fluorescent protein-fused lysosomal-associated membrane protein 1 (GFP-Lamp1). Lamp1 
is involved in the structural integrity of the lysosomal compartment and the regulation of 
lysosome/autophagosome fusion35,36. Although the transduction efficiency was moderate, 
some cells contained green hollow vesicles filled with 1 (red staining), further demonstrating 
that 1 accumulated within the lumen of lysosomes (Fig. 4b and Supplementary Fig. 4). In 
contrast, marmycin A did not accumulate in the Golgi apparatus, demonstrating that the 
small molecule is not a generic lipophilic membrane interacting agent (Supplementary Fig. 
5).
To evaluate the functional consequences of the accumulation of 1 in lysosomes, we 
monitored (by western blotting) the turnover of the ubiquitin-binding and oxidative stress 
response protein p62 as well as the autophagy marker protein LC3-II (Fig. 4c)37. We found 
that treatments with 1 resulted in a modest increase in p62 and LC3-II levels, indicating that 
1 had little influence on the autophagic flux. In comparison, the lysosome targeting agent 
chloroquine (CQ) induced significantly higher levels of both p62 and LC3-II, indicating a 
strong inhibition of the flux. Interestingly, co-treatment of cells with 1 and the ROS 
scavenger N-acetyl cysteine (NAC) prevented p62 induction by 1, but did not rescue cell 
viability. This result indicated that 1 induced some level of ROS, as a peripheral event and 
not the primary cause of cell death. Additionally, while CQ is known to inhibit the 
autophagic flux by increasing the pH in lysosomes37, the inability of 1 to inhibit autophagy 
suggested that this natural product had no effect on the lysosomal pH at the concentration 
used.
Lipophilic small molecules such as sphingosine have been shown to induce lysosomal 
membrane permeabilization (LMP) in some circumstances38–40, resulting in the 
translocation of lysosomal proteases within the cytosol. This, in turn, can promote the 
cleavage and activation of specific cytosolic proteins including the pro-apoptotic BH3 
interacting-domain death agonist protein (Bid), leading to mitochondrial outer membrane 
permeabilization (MOMP)41,42, cytochrome c release and caspases-dependent cell death. 
Because 1 contains a polar aminosugar fused to a lipophilic aromatic core and accumulates 
within the lysosomal compartment, we reasoned that 1 may also act as a detergent and 
trigger a similar response. Western blot analysis revealed a clear reduction of Bid protein 
upon treatment with 1 for 96 h (Fig. 4d). It is noteworthy that cleavage of Bid was prevented 
when cells were co-treated with the cathepsin B (CB) inhibitors E-64 and CA-074, or the 
chymotrypsin (CT) inhibitor TPCK, in strong agreement with LMP and the release of these 
lysosomal proteases within the cytosol. Consistent with this, 1 induced a destabilization of 
the lysosomal membrane, as indicated by the release of bulky FITC-dextran from lysosomes 
(Supplementary Fig. 6)39. Additionally, we also observed reduced levels of caspase 3, and 
cell viability was partially rescued when cells were co-treated with the caspase 3 inhibitors 
Z-DEVD-FMK or Z-VAD-FMK (Supplementary Figs 7 and 8).
The antimalarial and antiproliferative drug artesunate (20, Fig. 4e) has been shown to exert 
its activity by targeting the lysosomal compartment through Fenton-type chemistry43. We 
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therefore reasoned that a synthetic dimer of 1 and 20 would combine the properties of each 
substrate embedded within a single scaffold. Remarkably, we found that the synthetic dimer 
21 (which we named artesumycin) exhibited enhanced antiproliferative activity compared to 
1 and 20 when used either independently or as a co-treatment (Fig. 4e). For example, we 
found that 21 displayed an IC50 value of ~0.9 μM against the metastatic MDA-MB-231 
breast cancer cell line at 72 h incubation (Fig. 4f). In contrast, compounds 1 and 20 were 
poorly effective against this cell line at up to 10 μM when used independently, and 10 μM of 
each drug was required to reduce the number of viable cells by ~50%. These data indicate 
that 21 does not undergo hydrolysis in cells to release 1 and 20, strongly supporting a 
mechanistic synergy mediated by 21 against lysosomal integrity rather than independent 
additive effects of 1 and 20. It is noteworthy that 21 accumulated in the lysosomes, as 
confirmed by its co-localization with GFP-Lamp1, in line with the organelle-specific 
targeting capacity of 1 (Supplementary Fig. 9). Together, these data provide solid evidence 
for a novel model, whereby 1 induces cell death through lysosomal dysfunction, excluding 
direct genome targeting.
Discussion
We describe an expeditious synthetic route to 1. Our strategy features a straightforward one-
pot access to the angular aromatic core and its assembly with a vancosamine-derived 
aminosugar using a copper-catalysed cross-coupling followed by a challenging acid-
mediated cyclization. This synthetic sequence lends strong support to a plausible 
biosynthetic route involving similar intermediates, thereby establishing the absolute 
configuration of the marmycins by means of chemical synthesis from known precursors. 
Importantly, although natural sources of 1 are scarce, this synthesis allowed the production 
of sufficient quantities of material to identify some of the cellular events through which the 
natural product exerts its activity and the preparation of the more potent derivative 21. 
Unbiased strategies based on quantitative proteomics44 and high-throughput 
sequencing14,15 have previously enabled the identification of biological targets of small 
molecules in cells. Here, we have used high-resolution microscopy14,33 to identify, instead, 
a cellular organelle as the biologically relevant target of 1. In particular, we have discovered 
that 1 operates as a lysosomotropic small molecule (Fig. 5), suggesting that other 
structurally related compounds could trigger similar responses. The biology of the lysosome 
is complex. Small molecules capable of targeting this organelle can induce pleiotropic 
responses, making it difficult to detect and quantify each single event. This includes a partial 
or complete LMP, the release of proteases with redundant functions, and the activation of 
caspase-dependent and -independent pathways, among other processes. The current study 
shows that 1 induces the cleavage of Bid and caspase-dependent cell death. More work is 
required to delineate the fine details of this response, such as the occurrence of proteases/
caspase-independent cell death pathways40, which could take place on the basis that cell 
killing by 1 was not completely prevented by caspase inhibitors. It is also conceivable that 
the sudden release of the acidic content and metal ions from lysosomes upon treatment with 
1 contributed to cell death in a manner that did not directly implicate the translocation of 
lysosomal proteases, and so explicit cell death pathways remain open to question. 
Regardless, our results provide substantial evidence of an alternative mechanism of action of 
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a natural angucycline that does not involve genomic DNA. Targeting the lysosome to elicit 
cell death is emerging as an attractive therapeutic strategy for the treatment of 
cancers39,45,46. For example, the clinically approved drug CQ has been shown to prevent 
the relapse observed in certain cancers refractory to a DXR regimen47–50. Accordingly, 
marmycin A—and perhaps other angucyclines—represent valuable probes with which to 
study the biology of the lysosome, leaning towards unanticipated therapeutic applications for 
this class of natural products.
Methods
Cell culture and proliferation assays
U2OS, A2780 and MDA-MB-231 cells were purchased from ATCC and were maintained in 
McCoy’s 5A or RPMI 1640, respectively, supplemented with 10% fetal bovine serum (FBS) 
and 1× antibiotic–antimycotic (Gibco) and incubated at 37 °C with 5% CO2. Cell viability 
assays were carried out by plating 2,000 cells per well in 96-well plates. Cells were treated 
with the relevant drug for 24 h or 72 h, then incubated with CellTiter-Blue (20 μl/well) for 1 
h before recording fluorescence (560(20)Ex/590(10)Em) using a PerkinElmer Wallac 1420 
Victor2 Microplate Reader. For cell cycle analysis, cells were fixed in ice-cold 70% ethanol, 
stained with propidium iodide (10 mg ml–1 PI, 250 mg ml–1 RNase A, 0.5% BSA, 0.02% 
sodium azide in 1× PBS) and analysed by FACS on a CyFlow Ploidy Analyser from Partec.
Drugs and inhibitors
Marmycin A was prepared in the laboratory according to Fig. 2. Cells were treated with 10 
μM marmycin A for 24 h unless stated otherwise. Doxorubicin (Sigma) was used at 1 μM 
for 6 h (cell imaging) or 1 μM for 24 h (western blotting); chloroquine (Sigma) was used at 
100 μM for 24 h; N-acetyl cysteine (Sigma) was used at 2 mM for 24 h (2 h pre-treatment). 
Z-DEVD-FMK (BD Biosciences) was used at 100 μM for 24 h (30 min pre-treatment). Z-
VAD-FMK (BD Biosciences) was used at 100 μM for 24 h (30 min pretreatment). E-64 
(Sigma) was used at 15 μM (added 48 h after 1, cells harvested at 96 h). CA-074 Me (Enzo 
Life Sciences) was used at 1 μM (added 48 h after 1, cells harvested at 96 h). N-tosyl-L-
phenylalanine chloromethyl ketone (TPCK, Sigma) was used at 5 μM (added 48 h after 1, 
cells harvested at 96 h). Artesunate was purchased from Sigma.
Immunofluorescence analysis
U2OS cells were cultured and treated with 1 or DXR at ~40% confluence. LysoTracker Blue 
DND-22 (L7525, Life Technologies) and 1 were added and used without fixation in live cell 
imaging experiments. Fluorescence was recorded 10 min after the addition of both reagents. 
GFP-Lamp1 was transiently expressed in U2OS cells following the manufacturer’s 
instructions. Briefly, 5 μl of CellLight Lysosomes-GFP BacMam 2.0 (C10596, Life 
Technologies) was mixed well with 200 μM U2OS culture medium and added to each well 
of a 24-well plate loaded poly-L-lysine-treated coverslips. After 16 h incubation, cells were 
washed with PBS and treated with 1 (10 μM, 6 h). Cells were then washed with PBS, fixed 
for 12 min with 2% formaldehyde/PBS and permeabilized for 10 min with 0.1% Triton 
X-100/PBS, then washed with PBS. The Golgi apparatus was detected using an anti-RCAS1 
antibody (1/100, #12290, Cell Signaling) and anti-rabbit Alexa Fluor secondary antibody 
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(1/500, A-11008, Life Technologies). Coverslips were mounted with VectaShield mounting 
medium with or without DAPI (Vector Laboratories). Images were taken with Leica SP8 
microscope or Nikon Te(-E) inverted confocal microscopes equipped with a spinning disk 
Yokogawa CXU-X1 A1 (DND-22 experiment only). Data were analysed with ImageJ 
software (NIH).
Western blotting
Cells were treated as indicated in Figs 3 and 4, then washed twice with PBS and lysed with 
2× Laemmli buffer. Cell extracts were heated for 5 min at 95 °C, sheared through a 26-gauge 
needle and quantified with a Nanodrop 2000 (Thermo Scientific). Protein lysates (~100 μg) 
were loaded on a 4–20% Mini-PROTEAN TGX Stain-Free Gel (BioRad), resolved by SDS-
PAGE electrophoresis and transferred onto a nitrocellulose membrane (Amersham). Proteins 
were probed with the following antibodies: anti-β-actin (ab8226, Abcam), anti-H2AX 
(PA1-14198, Thermo Scientific), anti-γH2AX (#2577, Cell Signaling), anti-p21 (#2947, 
Cell Signaling), anti-p53 (#2524, Cell Signaling), anti-p-p53 (#9284, Cell Signaling), anti-
p62 (610,833, BD Transduction Laboratories), anti-LC3 (#2775, Cell Signaling), anti-Bid 
(#2002, Cell Signaling) and anti-Caspase 3 (#9665, Cell Signaling) and were diluted 1/1,000 
in 5% BSA, 0.1% Tween-20/TBS. The secondary antibodies were anti-rabbit HRP 
(A120-108P, Bethyl), anti-mouse HRP (A90-116P) and anti-donkey HRP (A140-107P, 
Bethyl). Antigens were detected by ECL (Amersham). Imaging was performed using a 
ChemiDoc XRS+ System.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgements
The authors thank the CNRS for funding, and the Imagif Cell Biology Unit, J.-F. Gallard and F. Blanchard for 
assistance with cell imaging, NMR spectroscopy and X-ray crystallography, respectively. R.R. thanks J.A. Yeoman, 
S. Müller, J.E. Moses, S.L. Buchwald, L. Johannes, M. Mehrpour and members of R.R.’s laboratory for discussions 
and proofreading of this manuscript. Research in R.R.’s laboratory is supported by the European Research Council 
(grant no. 647973), the Fondation pour la Recherche Médicale (grant no. AJE20141031486), the Emergence Ville 
de Paris Program and the Ligue Nationale Contre le Cancer.
References
1. Kharel MK, et al. Angucyclines: biosynthesis, mode-of-action, new natural products, and synthesis. 
Nat Prod Rep. 2012; 29:264–325. [PubMed: 22186970] 
2. Martin GDA, et al. Marmycins A and B, cytotoxic pentacyclic C-glycosides from a marine 
sediment-derived actinomycete related to the genus Streptomyces. J Nat Prod. 2007; 70:1406–1409. 
[PubMed: 17844998] 
3. Cottreau KM, et al. Diverse DNA-cleaving capacities of the jadomycins through precursor-directed 
biosynthesis. Org Lett. 2010; 12:1172–1175. [PubMed: 20175518] 
4. Sun D, Hansen M, Hurley L. Molecular basis for the DNA sequence specificity of the pluramycins. 
A novel mechanism involving groove interactions transmitted through the helix via intercalation to 
achieve sequence selectivity at the covalent bonding step. J Am Chem Soc. 1995; 117:2430–2440.
5. Hansen M, Yun S, Hurley L. Hedamycin intercalates the DNA helix and, through carbohydrate-
mediated recognition in the minor groove, directs N7-alkylation of guanine in the major groove in a 
sequence-specific manner. Chem Biol. 1995; 2:229–240. [PubMed: 9383425] 
Cañeque et al. Page 9













6. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med. 1998; 339:900–905. 
[PubMed: 9744975] 
7. Yang F, Kemp CJ, Henikoff S. Doxorubicin enhances nucleosome turnover around promoters. Curr 
Biol. 2013; 23:782–787. [PubMed: 23602475] 
8. Pang B, et al. Drug-induced histone eviction from open chromatin contributes to the 
chemotherapeutic effects of doxorubicin. Nature Commun. 2013; 4:1908. [PubMed: 23715267] 
9. Pigram WJ, Fuller W, Hamilton LD. Stereochemistry of intercalation: interaction of daunomycin 
with DNA. Nature. 1972; 235:17–19. [PubMed: 4550390] 
10. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nature Rev Cancer. 2009; 
9:338–350. [PubMed: 19377506] 
11. Korynevska A, et al. Mechanisms underlying the anticancer activities of the angucycline 
landomycin E. Biochem Pharmacol. 2007; 74:1713–1726. [PubMed: 17904109] 
12. Müller S, Kumari S, Rodriguez R, Balasubramanian S. Small-molecule-mediated G-quadruplex 
isolation from human cells. Nature Chem. 2010; 2:1095–1098. [PubMed: 21107376] 
13. Koirala D, et al. A single-molecule platform for investigation of interactions between G-
quadruplexes and small-molecule ligands. Nature Chem. 2011; 3:782–787. [PubMed: 21941250] 
14. Rodriguez R, et al. Small-molecule-induced DNA damage identifies alternative DNA structures in 
human genes. Nature Chem Biol. 2012; 8:301–310. [PubMed: 22306580] 
15. Rodriguez R, Miller KM. Unravelling the genomic targets of small molecules using high-
throughput sequencing. Nature Rev Genet. 2012; 77:5439–5444.
16. Yadav JS, et al. InBr3-catalyzed cyclization of glycals with aryl amines. Angew Chem Int Ed. 
2003; 42:5198–5201.
17. Ding C, et al. Synthesis study on marmycin A: preparation of the C3′-desmethyl analogues. J Org 
Chem. 2009; 74:6111–6119. [PubMed: 19610637] 
18. Maugel N, Snider BB. Efficient synthesis of the tetracyclic aminoquinone moiety of marmycin A. 
Org Lett. 2009; 11:4926–4929. [PubMed: 19803528] 
19. Bourcet E, Bröhmer MC, Nieger M, Bräse S. Synthetic studies towards marmycins A and B: 
development of the vinylogous aldol–aza-Michael domino reaction. Org Biomol Chem. 2011; 
9:3136–3138. [PubMed: 21424004] 
20. Mendoza A, Ishihara Y, Baran PS. Scalable enantioselective total synthesis of taxanes. Nature 
Chem. 2012; 4:21–25.
21. Rodriguez R, Chapelon A-S, Ollivier C, Santelli M. Stereoselective synthesis of CD-ring 
precursors of vitamin D derivatives. Tetrahedron. 2009; 65:7001–7015.
22. Rodriguez R, Adlington RM, Moses JE, Cowley A, Baldwin JE. A new and efficient method for o-
quinone methide intermediate generation: application to the biomimetic synthesis of (±)-alboatrin. 
Org Lett. 2004; 6:3617–3619. [PubMed: 15387562] 
23. Rodriguez R, et al. Total synthesis of cyercene A and the biomimetic synthesis of (±)-9,10-
deoxytridachione and (±)-ocellapyrone A. Tetrahedron. 2007; 63:4500–4509.
24. Eade SJ, et al. Biomimetic synthesis of pyrone-derived natural products: exploring chemical 
pathways from a unique polyketide precursor. J Org Chem. 2008; 73:4830–4839. [PubMed: 
18517253] 
25. Heinzman SW, Grunwell JR. Regiospecific synthesis of bromojuglone derivatives. Tetrahedron 
Lett. 1980; 21:4305–4308.
26. Carreño MC, Urbano A, Di Vitta C. Enantioselective Diels–Alder approach to C-3-oxygenated 
angucyclinones from (SS)-2-(p-tolylsulfinyl)-1,4-naphthoquinone. Chem Eur J. 2000; 6:906–913. 
[PubMed: 10826613] 
27. Brimacombe JS, Hanna R, Saeed MS, Tucker LCN. Convenient syntheses of l-digitoxose, l-
cymarose, and l-ristosamine. J Chem Soc. 1982:2583–2587.
28. Greven R, Jütten P, Scharf H-D. A new stereoselective route to branched-chain nitro and amino 
sugars: synthesis of both enantiomers of decilonitrose and avidinosamine. J Org Chem. 1993; 
58:3742–3747.
29. Baran PS, Maimone TJ, Richter JM. Total synthesis of marine natural products without using 
protecting groups. Nature. 2007; 446:404–408. [PubMed: 17377577] 
Cañeque et al. Page 10













30. Klemer A, Rodemeyer G. Simple synthesis of methyl 4,6-ortho-benzylidene-2-desoxy-alpha-d-
erythro-hexopyranosid-3-ulose. Chem Ber. 1974; 107:2612–2614.
31. Wolfe JP, Wagaw S, Marcoux J-F, Buchwald SL. Rational development of practical catalysts for 
aromatic carbon–nitrogen bond formation. Acc Chem Res. 1998; 31:805–818.
32. Sambiagio C, Marsden SP, Blacker AJ, McGowan PC. Copper catalysed Ullmann type chemistry: 
from mechanistic aspects to modern development. Chem Soc Rev. 2014; 43:3525–3550. [PubMed: 
24585151] 
33. Larrieu D, Britton S, Demir M, Rodriguez R, Jackson SP. Chemical inhibition of NAT10 corrects 
defects of laminopathic cells. Science. 2014; 344:527–532. [PubMed: 24786082] 
34. Enari M, et al. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor 
ICAD. Nature. 1998; 391:43–50. [PubMed: 9422506] 
35. Eskelinen E-L, Tanaka Y, Saftig P. At the acidic edge: emerging functions for lysosomal membrane 
proteins. Trends Cell Biol. 2003; 13:137–145. [PubMed: 12628346] 
36. Huynh KK, et al. LAMP proteins are required for fusion of lysosomes with phagosomes. EMBO J. 
2007; 26:313–324. [PubMed: 17245426] 
37. Klionsky DJ, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. 
Autophagy. 2012; 8:445–544. [PubMed: 22966490] 
38. Kågedal K, Zhao M, Svensson I, Brunk UT. Sphingosine-induced apoptosis is dependent on 
lysosomal proteases. Biochem J. 2001; 359:335–343. [PubMed: 11583579] 
39. Boya P, Kroemer G. Lysosomal membrane permeabilization in cell death. Oncogene. 2008; 
27:6434–6451. [PubMed: 18955971] 
40. Galluzzi L, Bravo-San Pedro JM, Kroemer G. Organelle-specific initiation of cell death. Nature 
Cell Biol. 2014; 16:728–736. [PubMed: 25082195] 
41. Li H, Zhu H, Xu C-J, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in 
the Fas pathway of apoptosis. Cell. 1998; 94:491–501. [PubMed: 9727492] 
42. Chipuk JE, Bouchier-Hayes L, Green DR. Mitochondrial outer membrane permeabilization during 
apoptosis: the innocent bystander scenario. Cell Death Differ. 2006; 13:1396–1402. [PubMed: 
16710362] 
43. Hamacher-Brady A, et al. Artesunate activates mitochondrial apoptosis in breast cancer cells via 
iron-catalyzed lysosomal reactive oxygen species production. J Biol Chem. 2011; 286:6587–6601. 
[PubMed: 21149439] 
44. Ziegler S, Pries V, Hedberg C, Waldmann H. Target identification for small bioactive molecules: 
finding the needle in the haystack. Angew Chem Int Ed. 2013; 52:2744–2792.
45. Li Y, et al. Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and 
recurrence of breast cancer. Nature Med. 2010; 16:214–218. [PubMed: 20098429] 
46. Kreuzaler P, Watson CJ. Killing a cancer: what are the alternatives? Nature Rev Cancer. 2012; 
12:411–424. [PubMed: 22576162] 
47. Shiraishi N, Akiyama S-I, Kobayashi M, Kuwano M. Lysosomotropic agents reverse multiple drug 
resistance in human cancer cells. Cancer Lett. 1986; 30:251–259. [PubMed: 3697945] 
48. Zamora JM, Beck WT. Chloroquine enhancement of anticancer drug cytotoxicity in multiple drug 
resistant human leukemic cells. Biochem Pharmacol. 1986; 35:4303–4310. [PubMed: 3466591] 
49. Vezmar M, Georges E. Reversal of MRP-mediated doxorubicin resistance with quinoline-based 
drugs. Biochem Pharmacol. 2000; 59:1245–1252. [PubMed: 10736425] 
50. Savarino A, Lucia MB, Giordano F, Cauda R. Risks and benefits of chloroquine use in anticancer 
strategies. Lancet Oncol. 2006; 7:792–793. [PubMed: 17012039] 
Cañeque et al. Page 11













Figure 1. Anthraquinone-containing natural products.
a, Molecular structures of marmycin A (1) and B (2), jadomycin B (3), hedamycin (4), the 
clinically approved anthracycline doxorubicin (DXR, 5) and landomycin E (6). b, 
Retrosynthetic analysis towards marmycin A precursors featuring a stepwise fusion of the 
aromatic and chiral sugar moieties and a regioselective cycloaddition.
Cañeque et al. Page 12













Figure 2. Chemical synthesis of the marmycins.
a, Synthesis of precursors of 1. (i) 9, 10, toluene, 100 °C, 16 h, then concentrated to dryness; 
MeOH, rt, 4 h, then K2CO3, rt, 1 h, 33%. (ii) Tf2O, Et3N, CH2Cl2, –78 °C, 6 h, 78%. (iii) 
Benzaldehyde dimethylacetal, PTSA, dimethylformamide (DMF), 95 °C (reduced pressure), 
12 h, 98%. (iv) (iPr)2EtN, MOMCl, CH2Cl2, rt, 72 h, 91%. (v) sec-Buthyllithium (1.6 M, 
hexane), THF, –40 °C, 90 min, 61%. (vi) O-benzyl hydroxylamine HCl salt, NaOAc, EtOH, 
rt, 2 h, 90%. (vii) Anhydrous CeCl3, methyllithium (3 M, diethoxymethane), THF, –78 °C, 1 
h; then 16, –78 °C to rt, 1 h, 72%. (viii) H2, Pd/C (10 mol%), MeOH, rt, 12 h, 88%. (ix) 7, 8, 
CuI (20 mol%), K2CO3, toluene, 160 °C, sealed tube, 72 h, 33%. b, Assembly of aromatic 
and sugar moieties. (x) BF3·Et2O, CH2Cl2, –78 °C to rt, 24 h, 42%. (xi) NaH, DMF, 0 °C, 2 
h, 75%. (xii) 50% wt/wt aq. HBF4, MeCN, 82 °C, 8 h, 13%. (xiii) NCS, C2H4Cl2, 84 °C, 24 
h, 61%. c, ORTEP drawing of the X-ray crystal structure of 1 showing top and side views. rt, 
room temperature.
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Figure 3. Marmycin A kills human cancer cells independently of genome targeting.
a, Percentage of viable U2OS cells after 72 h treatment with DXR (dashed line) or 1 (black). 
n = 3. Error bars, s.d. b, Confocal microscopy images showing accumulation of DAPI (pan-
nuclear blue), DXR (pan-nuclear red) and 1 (red puncta) in U2OS cells. Yellow boxes 
indicate the area of magnification of the main images. Zoomed images are ×5. Scale bar, 10 
μm. c, Western blot analysis showing levels of γH2AX, p-p53 and p21 in U2OS cells treated 
with dimethylsulfoxide (DMSO), DXR or 1 (50 μM, 24 h) including a co-treatment with Z-
DEVD-FMK.
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Figure 4. Marmycin A accumulates in the lysosomes and triggers programmed cell death.
a, Live imaging of U2OS cells co-treated with 1 and DND-22. The yellow box indicates the 
area of magnification of the main image. The zoomed image is ×3. White arrowheads 
indicate sites of co-localization. The white box represents a further ×3 magnification. b, 
Confocal microscopy images of U2OS cells expressing GFP-Lamp1 treated with 1. Yellow 
boxes indicate the area of magnification of the main images. Zoomed images are ×5. White 
arrowheads indicate sites of co-localization. The white box shows a further ×3 
magnification. Scale bars, 10 μm. c, WB analysis of p62 and LC3 in U2OS cells treated with 
DMSO, CQ or 1 (50 µM, 24 h) including a co-treatment with NAC. d, Western blot analysis 
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of Bid in U2OS cells treated with DMSO or 1 (10 µM, 96 h) including a co-treatment with 
CB or CT inhibitors. n.i., no inhibitor. e, Molecular structures of 20 and 21. f, Percentage of 
viable MDA-MB-231 cells after 72 h treatment with DXR (dashed line), 1 (black), 20 
(cyan), 21 (red) and an equimolar mixture of 1 and 20 (blue). n = 3; error bars, s.d.
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Figure 5. Antiproliferative mechanisms of anthraquinone-containing drugs.
Black arrows indicate previously established mechanisms. Red arrows highlight the cellular 
activity of marmycin A. Black arrows with question marks indicate putative mechanisms of 
action of other anthraquinone-containing small molecules.
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